Stockscreener 앱 받기
3.42
0.58%
-0.02
전일 마감가:
$3.44
열려 있는:
$3.46
하루 거래량:
951.21K
Relative Volume:
1.24
시가총액:
$645.63M
수익:
$12.99M
순이익/손실:
$-74.39M
주가수익비율:
-7.7727
EPS:
-0.44
순현금흐름:
$-78.92M
1주 성능:
+3.95%
1개월 성능:
+6.54%
6개월 성능:
-11.63%
1년 성능:
+18.75%
1일 변동 폭
$3.40
$3.515
1주일 범위
$3.3012
$3.515
52주 변동 폭
$2.30
$4.725
Arbutus Biopharma Corp Stock (ABUS) Company Profile
명칭
Arbutus Biopharma Corp
전화
604-419-3200
주소
701 VETERANS CIRCLE, WARMINSTER, PA
ABUS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
3.42 | 645.63M | 12.99M | -74.39M | -78.92M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-02-02 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-25 | 개시 | Jefferies | Hold |
| 2020-12-17 | 개시 | H.C. Wainwright | Buy |
| 2020-07-27 | 재개 | JMP Securities | Mkt Outperform |
| 2020-07-24 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-05-19 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-03-06 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2020-02-20 | 개시 | Robert W. Baird | Outperform |
| 2020-02-05 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-10-07 | 재확인 | B. Riley FBR | Buy |
| 2019-10-04 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2018-10-16 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-10-15 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2018-10-12 | 재확인 | Chardan Capital Markets | Buy |
| 2018-07-06 | 다운그레이드 | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-03-19 | 재개 | Chardan Capital Markets | Buy |
| 2018-03-19 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-01-05 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-04-04 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2017-02-01 | 재확인 | Wedbush | Outperform |
| 2016-12-13 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2016-11-30 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
모두보기
Arbutus Biopharma Corp 주식(ABUS)의 최신 뉴스
Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So. - The Motley Fool
Arbutus Biopharma's CFO David Hastings sells shares worth $72,826 - MSN
The Hidden Gem in Nasdaq’s Under $5 Club: Is Arbutus Biopharma the Next Big Thing? - Jomfruland.net
Is Arbutus Biopharma Corp. (ABUS) the Best Nasdaq Stock Under $5 to Buy? - Insider Monkey
Ebola Virus Vaccine Market May See a Big Move| Arbutus Biopharma, BioCryst Pharmaceuticals - openPR
SG Americas Securities LLC Purchases 16,250 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Corp (ABUS) Stock: A Look at the Monthly Trend - The News Heater
Jefferies analysts upgrades a Buy rating for Arbutus Biopharma Corp (ABUS) - Knox Daily
Arbutus Biopharma Executives Sell Shares to Cover Tax Obligations - TradingView
Arbutus Biopharma Corp (ABUS) expanding its growth trajectory ahead - SETE News
Morgan Stanley Reduces Stake in Arbutus Biopharma Corp - GuruFocus.com
JPMorgan Chase & Co. Increases Stock Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Ballentine Partners LLC Acquires New Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Corp. to Host Earnings Call - ACCESS Newswire
Arbutus Biopharma (NASDAQ:ABUS) Receives “Buy” Rating from HC Wainwright - Defense World
Arbutus Biopharma (NASDAQ:ABUS) Receives "Buy" Rating from HC Wainwright - MarketBeat
Arbutus Biopharma Sets Sights on Advancing HBV Cure in 2025 - MyChesCo
Jim Cramer on Arbutus Biopharma Corporation (ABUS): ‘It Loses Money’ - Insider Monkey
Barclays PLC Purchases 223,995 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Cramer's Lightning Round: Arbutus Biopharma is 'the ultimate spec' - MSN
Arbutus Provides 2025 Corporate and Financial Update - GlobeNewswire
Arbutus Biopharma Achieves 50% Cure Rate in Hepatitis Trial, Advances to Phase 2b with $123M Cash - StockTitan
Jane Street Group LLC Has $258,000 Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Principal Financial Group Inc. Sells 12,352 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma (NASDAQ:ABUS) Sees Large Volume IncreaseShould You Buy? - MarketBeat
Arbutus: Positive Imdusiran Data Leads To Phase 2B Development (NASDAQ:ABUS) - Seeking Alpha
Geode Capital Management LLC Buys 135,442 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Barclays PLC Acquires 223,995 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - MarketBeat
State Street Corp Increases Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - MarketBeat
State Street Corp Purchases 1,472,652 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Co. (NASDAQ:ABUS) Position Boosted by XTX Topco Ltd - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $754,000 in Arbutus Biopharma Co. (NASDAQ:ABUS) - MarketBeat
Arbutus Biopharma's SWOT analysis: hepatitis B focus drives stock potential - Investing.com
Arbutus Biopharma (NASDAQ:ABUS) Shares Gap DownHere's Why - MarketBeat
Charles Schwab Investment Management Inc. Grows Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Charles Schwab Investment Management Inc. Purchases 831,663 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - MarketBeat
Large Shareholder Urges Warminster-based Arbutus to Seek Partners Instead of Selling More Stock - MSN
Intech Investment Management LLC Takes Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Here’s Why Arbutus (ABUS) Surged in Q3 - Yahoo Finance
Arbutus Biopharma's SWOT analysis: focus on CHB treatment drives stock outlook - Investing.com
Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors - The Bakersfield Californian
Arbutus Biopharma's HBV Trial Hits 50% Cure Rate; Major Investor Urges Strategic Partnership - StockTitan
Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Update - MarketBeat
Arbutus Biopharma (STU:I9DN) 9-Day RSI : 39.19 (As of Dec. 01, 2024) - GuruFocus.com
Principal Financial Group Inc. Reduces Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat - Yahoo Finance
Arbutus Biopharma Corp (ABUS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Arbutus Biopharma Corp 주식 (ABUS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sims Karen | Chief Medical Officer |
Feb 04 '25 |
Sale |
3.28 |
19,348 |
63,519 |
106,194 |
| McElhaugh Michael J. | Interim President & CEO |
Feb 04 '25 |
Sale |
3.28 |
23,790 |
78,103 |
1,481,003 |
| Naftzger J. Christopher | General Counsel and CCO |
Feb 04 '25 |
Sale |
3.28 |
11,333 |
37,206 |
86,244 |
0.27%
3.05%
자본화:
|
볼륨(24시간):